ID   TALL-104
AC   CVCL_2771
DR   BTO; BTO:0003740
DR   CLO; CLO_0009267
DR   AddexBio; C0003027/NA
DR   ATCC; CRL-11386
DR   BioSample; SAMN03471335
DR   Cosmic; 683541
DR   Cosmic; 2602910
DR   GEO; GSM5137746
DR   PRIDE; PXD023662
DR   Wikidata; Q54971691
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   Patent=US5272082;
RX   PubMed=1706955;
RX   PubMed=2039829;
RX   PubMed=11059767;
RX   PubMed=15361874;
RX   PubMed=17170727;
RX   PubMed=35354797;
WW   http://www.galileoresearch.it/en/pipeline/TALL-104.html
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11386.
CC   Characteristics: IL2 dependent.
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 8064; NUP214; Name(s)=NUP214-ABL1; Note=NUP214 exon 32 fused to ABL1 exon 2 (PubMed=15361874; PubMed=35354797).
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Miscellaneous: STR profile from personal communication of Leo I.R.
CC   Discontinued: AddexBio; C0003027; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): ATCC; Direct_author_submission
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D10S1248: 13,14
ST   D12S391: 22,23
ST   D13S317: 9,12
ST   D16S539: 12
ST   D18S51: 12,13
ST   D19S433: 14.2,15
ST   D1S1656: 16
ST   D21S11: 30,31
ST   D22S1045: 11,16
ST   D2S1338: 20,25
ST   D2S441: 11
ST   D3S1358: 15,18
ST   D5S818: 12,13
ST   D7S820: 7,13
ST   D8S1179: 11,14
ST   DYS391: 10
ST   FGA: 21,22
ST   SE33: 16,19
ST   TH01: 7,9
ST   TPOX: 8,9
ST   vWA: 14,18
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   2Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 24
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   Patent=US5272082;
RA   Santoli D., Rovera G., Cesano A.;
RT   "Cytotoxic T-ALL cell lines and uses therefor.";
RL   Patent number US5272082, 21-Dec-1993.
//
RX   PubMed=1706955; DOI=10.1182/blood.V77.7.1534.1534;
RA   O'Connor R., Cesano A., Lange B., Finan J., Nowell P.C., Clark S.C.,
RA   Raimondi S.C., Rovera G., Santoli D.;
RT   "Growth factor requirements of childhood acute T-lymphoblastic
RT   leukemia: correlation between presence of chromosomal abnormalities
RT   and ability to grow permanently in vitro.";
RL   Blood 77:1534-1545(1991).
//
RX   PubMed=2039829; DOI=10.1182/blood.V77.11.2463.2463;
RA   Cesano A., O'Connor R., Lange B., Finan J., Rovera G., Santoli D.;
RT   "Homing and progression patterns of childhood acute lymphoblastic
RT   leukemias in severe combined immunodeficiency mice.";
RL   Blood 77:2463-2474(1991).
//
RX   PubMed=11059767;
RA   Kruse C.A., Visonneau S., Kleinschmidt-DeMasters B.K., Gup C.J.,
RA   Gomez G.G., Paul D.B., Santoli D.;
RT   "The human leukemic T-cell line, TALL-104, is cytotoxic to human
RT   malignant brain tumors and traffics through brain tissue: implications
RT   for local adoptive immunotherapy.";
RL   Cancer Res. 60:5731-5739(2000).
//
RX   PubMed=15361874; DOI=10.1038/ng1425;
RA   Graux C., Cools J., Melotte C., Quentmeier H., Ferrando A.A., Levine R.,
RA   Vermeesch J.R., Stul M., Dutta B., Boeckx N., Bosly A., Heimann P.,
RA   Uyttebroeck A., Mentens N., Somers R., MacLeod R.A.F., Drexler H.G.,
RA   Look A.T., Gilliland D.G., Michaux L., Vandenberghe P., Wlodarska I.,
RA   Marynen P., Hagemeijer A.;
RT   "Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute
RT   lymphoblastic leukemia.";
RL   Nat. Genet. 36:1084-1089(2004).
//
RX   PubMed=17170727; DOI=10.1038/sj.leu.2404486;
RA   Sandberg Y., Verhaaf B., van Gastel-Mol E.J., Wolvers-Tettero I.L.M.,
RA   de Vos J., MacLeod R.A.F., Noordzij J.G., Dik W.A., van Dongen J.J.M.,
RA   Langerak A.W.;
RT   "Human T-cell lines with well-defined T-cell receptor gene
RT   rearrangements as controls for the BIOMED-2 multiplex polymerase chain
RT   reaction tubes.";
RL   Leukemia 21:230-237(2007).
//
RX   PubMed=35354797; DOI=10.1038/s41467-022-29224-5;
RA   Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T.,
RA   Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E.,
RA   Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I.,
RA   Lehtio J., Vesterlund M., Jafari R.;
RT   "Integrative multi-omics and drug response profiling of childhood
RT   acute lymphoblastic leukemia cell lines.";
RL   Nat. Commun. 13:1691.1-1691.19(2022).
//